Outcome of Autologous Stem Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma - A Single Center Study
References
- Senapati J, Devasia AJ, Korula A, Fouzia NA, Kulkarni U, Lakshmi KM, et al. Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma-A Single Center Experience. Indian J Hematol Blood Transfus. 2022;38(2):290–8.
- Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–4.
- Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.
- Mariotti J, Ricci F, Giordano L, Taurino D, Sarina B, De Philippis C, et al. Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens. Cells. 2024;13(2).
- Caserta S, Martino EA, Skafi M, Alvaro ME, Bruzzese A, Amodio N, et al. Beyond PD-1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next-Generation Immune Strategies. Eur J Haematol. 2026;116(4):357–67.
- Greco R, Ruggeri A, McLornan DP, Snowden JA, Alexander T, Angelucci E, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplant. 2025;60(11):1499–525.
- Ali N, Adil SN, Shaikh MU. Autologous Hematopoietic Stem Cell Transplantation—10 Years of Data From a Developing Country. Stem Cells Translational Medicine. 2015;4(8):873–7.
- Ali N, Iftikhar R, Ayaz Mir M, Bokhari SW, Rehman JU, Zaidi U, et al. Haematopoietic Stem Cell Transplant Trends in Pakistan: Activity Survey from Pakistan Bone Marrow Transplant Group. J Transplant. 2023;2023:8865364.
- Hidayat I, Khan MA, Awan MN, Siddiq A, Shamim N, Khan H. Outcomes of Autologous Haematopoietic Stem Cell Transplant in Lymphomas: A Single Centre Study. J Coll Physicians Surg Pak. 2025;35(4):508–12.
- Kumar S, Sharma A, Bakhshi S, Pushpam D, Gogia A, Sahoo RK, et al. Autologous Stem Cell Transplantation in Adult Hodgkin Lymphoma at a Tertiary Care Center in India: Analysis of Outcomes and Prognostic Factors. Indian J Hematol Blood Transfus. 2024;40(2):181–9.
- WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon, France: International Agency for Research on Cancer; 2017.
- Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(5):589–97.
- Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.
- Van Den Neste E, Casasnovas O, Andre M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98(8):1185–95.
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
- Akhtar S, Rauf SM, Elhassan TA, Maghfoor I. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Ann Hematol. 2016;95(9):1521–35.
- Iftikhar J SH, Sheikh F, Shah MI, Khan SI, Bakar MA, Siddiqui N. Evaluation of Prognostic Factors in Patients with Relapsed Hodgkin’s Lymphoma Undergoing Autologous Stem Cell Transplant. Pak Armed Forces Med J 2021;Vol. 71 No. 5(October):1833–8.
- Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, et al. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clinical lymphoma, myeloma & leukemia. 2021;21(2):132–8.
- Shafi RG, Al-Mansour MM, Kanfar SS, Al Hashmi H, Alsaeed A, Al-Foheidi M, et al. Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia. Oncol Res Treat. 2017;40(5):288–92.
- Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood. 2018;131(15):1689–97.
- Brockelmann PJ, Muller H, Gillessen S, Yang X, Koeppel L, Pilz V, et al. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia. 2022;36(3):772–80.
- Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013;19(3):410–7.
- Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665–70.
- Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625–33.
- Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–25.
- Sucak GT, Cakar MK, Suyani E, Aki Z, Altindal S, Acar K. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013;18(5):269–76.
- Shah GL, Yahalom J, Matasar MJ, Verwys SL, Goldman DA, Bantilan KS, et al. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Br J Haematol. 2016;175(3): 440–7.
- Roerden M, Sokler M, Kanz L, Bethge W, Vogel W, Walz JS. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience. Ann Hematol. 2020;99(2):265–76.
- Husi K, Szabo R, Pinczes LI, Foldeak D, Dudley R, Szomor A, et al. Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary. Ann Hematol. 2023;102(9): 2555–63.
- Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya- Feldstein J, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148(6):890–7.
- Wu R, Ma L. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Cell Transplant. 2023;32:9636897231179364.
- Krawiec K, Strzalka P, Racinska O, Kedzior M, Sowul H, Salamon W, et al. Evaluation of outcome and safety profile in high-dose BEAM and Benda- EAM chemotherapy with subsequent autologous stem cell transplantation in lymphoma patients. Contemp Oncol (Pozn). 2024;28(2):158–66.
- Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008;19(7):1312–9.
- Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood. 2017;130(21):2265–70.
- Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2008;111(4):2339–46.
- Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812–26.
- Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A. The role of PET/ CT in the modern treatment of Hodgkin lymphoma. Cancer Treat Rev. 2019;77:44–56.
DOI: https://doi.org/10.2478/jcas-2026-0011 | Journal eISSN: 2411-989X
Language: English
Page range: 70 - 77
Published on: Jun 29, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Related subjects:
© 2026 Nouman Nawaz Ali, Natasha Ali, Mohammad Usman Shaikh, Madiha Noor, Munira Moosajee, Salman Naseem Adil, published by Shakuat Khanum Memorial Cancer Hospital and Research Centre
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.